MaxCyte, Inc. 2022 Q3 Form 10-Q Summary
Business Context and Reporting Period
MaxCyte is a commercial cell-engineering company whose Flow Electroporation and ExPERT platforms support cell therapy, drug discovery, biomanufacturing and related research. Revenue is generated primarily from instrument and processing-assembly sales, instrument leases, licenses and strategic platform license milestone economics. This unaudited Form 10-Q covers the three and nine months ended September 30, 2022, compared with the same periods in 2021.
Key Financial Metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Revenue | $10.6 million | $10.1 million | $31.8 million | $23.7 million |
| Gross profit | $9.3 million | $9.2 million | $28.3 million | $21.3 million |
| Gross margin | 87% | 91% | 89% | 90% |
| Operating loss | $(7.7) million | $(2.4) million | $(20.6) million | $(13.2) million |
| Net loss | $(6.4) million | $(2.7) million | $(18.8) million | $(14.2) million |
| Net loss per share | $(0.06) | $(0.03) | $(0.18) | $(0.16) |
| Cash used in operating activities | Not separately provided | Not separately provided | $(8.7) million | $(9.7) million |
- Q3 revenue increased 5%; nine-month revenue increased 34%.
- Nine-month revenue by market was $23.0 million from cell therapy, $6.1 million from drug discovery and $2.8 million from program-related revenue.
- Operating expenses increased to $17.0 million in Q3 and $48.9 million for the nine-month period, driven by higher research and development, sales and marketing, general and administrative, and depreciation expenses.
- Cash and cash equivalents were $43.0 million at September 30, 2022, and short-term investments were $189.9 million, for total cash and short-term investments of $232.9 million.
- Total assets were $286.4 million and accumulated deficit was $133.1 million at September 30, 2022.
- The company reported no indebtedness following repayment of its MidCap term loan in March 2021. Operating lease liabilities totaled $15.0 million at September 30, 2022.
Material Changes Versus the Prior Comparable Period
- Q3 cell therapy revenue increased 27% to $7.9 million, while drug discovery revenue increased 4% to $2.0 million. Program-related revenue declined 62% to $0.8 million because milestone timing is variable.
- For the first nine months, cell therapy revenue increased 46%, primarily from instrument sales and licenses and disposable sales. Drug discovery revenue increased 10%, and program-related revenue increased 10%.
- Q3 gross margin declined to 87% from 91%; nine-month gross margin declined to 89% from 90%, primarily because of revenue mix.
- Q3 research and development expense increased 94%, sales and marketing expense increased 40%, and general and administrative expense increased 21%. Nine-month increases were 15%, 49% and 60%, respectively.
- Interest income increased materially because of higher short-term investment balances following the 2021 IPO and higher interest rates. The company had no interest expense on debt in Q3 2022.
- Property and equipment increased to $23.0 million from $7.7 million at year-end 2021, largely reflecting leasehold improvements and laboratory investments. Operating lease right-of-use assets increased to $10.0 million from $5.7 million.
- Net cash used in operating activities improved to $8.7 million from $9.7 million for the comparable nine-month period. Financing cash inflow was only $1.7 million in 2022, versus $233.5 million in 2021, which included the IPO proceeds.
Guidance, Outlook, Risks and Unusual Items
- Management expects continued revenue growth over time as customer programs advance, the installed base expands, disposable usage increases and additional strategic platform license agreements are signed. No quantified financial guidance is provided in the filing.
- Management expects continued net losses and higher operating expenses as it expands sales, marketing, manufacturing, research and development, product offerings and public-company infrastructure. Based on its current business plan, management believes existing cash and investments will fund operations and capital expenditures for the foreseeable future, although this depends on assumptions that may prove incorrect.
- MaxCyte signed strategic platform license agreements with LG Chem in July 2022 and Vertex Pharmaceuticals in September 2022, and expects additional agreements, but the timing and amount of future milestone and sales-based payments remain uncertain.
- The business is exposed to customer and partner concentration: one customer represented 26% of Q3 revenue and 28% of nine-month revenue, and 29% of accounts receivable at September 30, 2022.
- Supply-chain risk remains significant because components and raw materials are sourced from a limited number of suppliers. The company increased inventory levels to mitigate potential disruptions related to geopolitical tensions, COVID-19 and the Russia-Ukraine conflict.
- The company remains dependent on adoption of its technology, partner development and regulatory milestones, a limited product portfolio, competitive pressures, long sales cycles and fluctuating quarterly milestone revenue.
- The new headquarters lease has a stated term through August 31, 2035, with $29.6 million of incremental non-cancellable payments. The landlord had reimbursed $3.5 million of tenant improvements, with $0.8 million of reimbursement receivables outstanding at September 30, 2022.
- The company incurred a write-off of leasehold improvements related to early termination of prior facility subleases. No material legal proceedings were reported, and management stated that disclosure controls were effective as of September 30, 2022.
Important Facts for Investors to Verify
- Whether revenue growth, particularly cell therapy disposables and instrument licenses, continues to offset variability in strategic platform license milestones.
- The pace at which operating expenses and capital investments translate into revenue growth and whether operating cash burn remains manageable.
- The sustainability of gross margins amid changing mix among instruments, processing assemblies, leases and milestone revenue.
- Customer and partner concentration, including the contribution and development progress of major strategic platform license partners.
- Cash runway under scenarios involving slower customer adoption, delayed clinical milestones, supply-chain disruption or additional capital requirements.
- Execution of the new headquarters and manufacturing expansion, including total lease and construction-related commitments.
- The effect of stock-based compensation, which totaled $8.6 million for the first nine months of 2022, and potential dilution from approximately 16.1 million anti-dilutive shares excluded from loss-per-share calculations.